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Heart failure is an enormous problem. Data from the Framingham heart study shows that it develops in approximately 16% of men and 18% of women who have diabetes; 12% of men and 8% of women who have hypertension; and 30% of both sexes who have myocardial infarction.
1 Interestingly, over the second half of the 20th century there has been a striking increase in the frequency of coronary artery disease and diabetes as aetiological factors for CHF, whereas the impact of hypertension and rheumatic valve disease has declined.
Heart structure and function LVD produces many changes in the structure and function of the heart through a variety of mechanisms.
The muscle of the heart is encased in a collagen weave. There are interstitial spaces that are associated with a variety of elements, a number of which can contribute to the development of CHF. The extracellular matrix has a scaVolding function, which supports myocytes and blood vessels. It also provides lateral connections between the cells and muscular bundles that govern not only the architecture of the heart, but also its ability to contract. Moreover, the extracellular matrix contributes to the heart's tensile strength and resilience, which helps resist deformation, maintaining the elliptical shape of the heart and its thickness.
Ventricular remodelling
Once left ventricular dysfunction occurs a series of compensatory mechanisms are triggered which lead to a host of structural and neurohormonal adaptations. Haemodynamic, neurohormonal, and molecular factors operate to modulate remodelling of the left ventricle and vascular tree (fig 1) . Ventricular remodelling is the ability to reconstruct the heart as a result of myocardial damage, with changes in ventricular thickness and size. These apply to the subcellular, the cellular, the tissue, and the chamber levels of the heart.
Following myocardial infarction, one phenomenon that is known to occur is ventricular expansion. With expansion of the ventricle there is dilatation and thinning which can occur without additional necrosis. There is also a distortion in the shape of the heart from an elliptical to a more spherical form. This contributes to substantial mechanical ineYciency and worsening of CHF.
There is an important relation between the size of the heart and patient outcome, with a progressive rise in mortality as end systolic and end diastolic volume increase.
2 Reperfusion is critically important for ventricular healing and reducing the risk of ventricular aneurysm, which is an important precursor of CHF.
Neurohormonal network and LVD
A number of neurohormones may be triggered as a result of myocardial dysfunction (fig 2) . These neurohormones have both vasodilator and vasoconstrictor eVects and provide a number of therapeutic opportunities.
One of the key neuroendocrine axes is the renin-angiotensin system. The other major neurohormonal axis operational in heart failure is the sympathetic nervous system. The interaction between these two systems is complex.
RENIN-ANGIOTENSIN SYSTEM
The renin-angiotensin system is one of the major neuroendocrine axes involved in the development of heart failure. Inhibition of this system therefore has important therapeutic eVects. For example, angiotensin converting enzyme (ACE) inhibitors have a dual mechanism. Firstly, they inhibit the conversion of angiotensin I to angiotensin II and therefore reduce vasoconstriction and cell proliferation. Secondly, they inhibit the breakdown and metabolism of bradykinin and therefore increase the production of prostaglandins and nitric oxide. The importance of this second mechanism is still being debated.
ALDOSTERONE
The emergence of aldosterone as an important player in CHF has recently been re-emphasised by survival benefits associated with spironolactone in the RALES study. 3 Aldosterone is known to have multiple eVects including sodium retention, potassium loss, increasing blood pressure, and baroreceptor dysfunction. In addition there is experimental evidence that spironolactone's antifibrotic eVect may protect the matrix of the heart from unfavourable remodelling. 4 
CATECHOLAMINES
Catecholamines have a number of adverse eVects related to heart failure. These include diminishing the ability of heart failure patients to respond to the demands of exercise by increasing both oxygen consumption and energy depletion. They are also involved in arrhythmogenesis, hypertrophy, alteration of the geometry of the heart, and potentiation of cell death and fibrosis.
APOPTOSIS
One important and recently appreciated phenomenon related to myocardial dysfunction is programmed cell death, or apoptosis, which may be important in the genesis and the worsening of CHF. Cardiac abnormalities may stimulate cytokines and growth factors, and with an increase in intracellular calcium and oxidative stress there may be apoptosis and progression of CHF.
Treatment

THERAPEUTIC GOALS
The therapeutic goals in CHF are to enhance the quality of life of patients, improve survival, halt disease progression, and reverse the disease process. Above all, treatment should do no harm.
The ideal pharmacotherapy for heart failure would: x reduce heart rate; x reduce oxygen consumption; x reduce neurohormonal activation; x restore autonomic balance; x enhance tissue and coronary perfusion; x reduce circulatory congestion; x promote favourable cardiac and vascular remodelling; x restore cardiac size and shape.
ACE INHIBITION
The largest body of clinical trial evidence exists for the favourable benefits of ACE inhibitors in post-myocardial infarction or CHF patients with LVD. They have therefore become the standard of care for patients with LVD irrespective of symptoms.
In a study of patients soon after myocardial infarction, increases in diastolic and systolic volume occurred in patients receiving placebo. 5 However, treatment with the ACE inhibitor captopril preserved diastolic and systolic volumes. This eVect was maintained after withdrawal of treatment, suggesting that it was not drug dependent but had been associated with structural remodelling that persisted after withdrawal of the ACE inhibitor.
The SOLVD study found that, if patients had not suVered myocardial infarction or angina, they did much better than those who had. 6 This emphasises the catastrophic impact of myocardial infarction in patients with established heart failure. Interestingly, ACE inhibitors have an independent eVect on the reduction of myocardial infarction. Data from the SAVE study showed a reduction in the frequency of myocardial infarction with ACE inhibition (fig 3) . 7 The protective eVects of ACE inhibitors therefore not only relate to their eVects on the left ventricle but also on the coronary tree itself. In fact, a review of data from SOLVD, SAVE, and AIRE shows an overall 21% reduction in the risk of myocardial infarction in CHF patients when treated with ACE inhibitors. There are a number of mechanisms by which ACE inhibitors may reduce vascular events in patients with CHF: x antihypertensive eVect; x anti-renin eVect; x enhancement of coronary endothelial function; x antiproliferative eVect; x antiplatelet activity; x modulation of fibrinolytic balance.
SPIRONOLACTONE
In the RALES study 1600 patients with New York Heart Assocation (NYHA) functional class III and IV heart failure, who had diminished ejection fractions and were receiving diuretics and, for the most part, ACE inhibitors, were given spironolactone in doses of 25 mg to 50 mg daily. 3 The study was terminated early because of a striking reduction in all cause mortality of 27%, and a commensurate reduction in cardiovascular hospitalisations with spironolactone. For 1000 patients treated for two years, there were 72 lives saved and 264 hospitalisations prevented. The introduction of spironolactone is therefore an important addition to the therapeutic armamentarium for CHF.
BLOCKERS
Recently new and compelling evidence from a number of sources supports the use of blocker treatment. Blockers provide incremental benefit by reversing LVD and enhancing survival in patients already receiving ACE inhibitor treatment. For example, the MERIT and CIBIS-2 studies provide strong evidence of the benefits of metoprolol and bisoprolol. 9 10 
Conclusion
William Ostler said: "One should treat as many patients as possible with a new drug, while it still has the power to heal." There are now many therapeutic options for heart failure. It is therefore important that the evidence to support them is certain before they are used in patients. There is solid and convincing evidence that ACE inhibitors and blockers, and emerging evidence that aldosterone antagonism, can provide enhanced survival and new hope for the legions of patients worldwide who are aZicted with heart failure. There are other agents which show promise but which need further study before their introduction into clinical practice. 
